NeoGenomics Laboratories’ Post

Check out Neo’s lite paper demonstrating the prevelance of RET fusions across 18 tumor types #rwd #precisionmedicine #precisiononcology

With over 25 years of experience in research, technology, and biotech, Noelle Gaskill of Mirati Therapeutics approaches the challenges of DCTs with a comprehensive perspective, prioritizing listening to research sites. Get a sneak peek into her #ACRP2024 session, where she shares tactical insights from collaborating with thought-leaders, regulators, and sites, aiming to launch a hybrid DCT interventional oncology trial this year. Learn more about Noelle's session in Anaheim > https://bit.ly/3T5ahLX #GoForIt #GoForEducation #ClinicalTrials #ClinicalResearch #ClinicalTrialDesign #DCT #DecentralizedClinicalTrials

ASCO 2024 was incredible. This whitepaper was a blast to write! Thanks Magnolia Innovation for making this possible & striving to be leaders in oncology! #precisionmedicine #asco2024 #healthsciences #consulting #oncology #experts

Yesterday, STAT published an insightful article on the #radiopharmaceutical space. It is indeed a "boom time" for those of us working to develop #radioligandtherapy (#RLT), and it’s great to hear there is interest in radiopharma as a potential "next wave of therapeutics for oncology." We agree! The field is not without challenge as the short-lived nature of the isotopes requires synchronized supply chains and isotope generation. Several CDMOs have stepped up their investment in the space to create distributed manufacturing networks that are more resilient than centralized approaches. This commitment was highlighted in a recent article in Endpoints News. At ARTBIO, we’re developing a pipeline of alpha radioligand therapeutics with Pb212 – our Alphadirect technology provides an accessible and reliable source of Pb212. We are deploying our technology across a network of centers, overcoming the obstacles of limited supply and manufacturing challenges to reliably deliver therapies to patients. It takes a village of partners to deliver technologies and therapies and we are delighted to work with SpectronRx on the manufacturing of key components of AlphaDirect and look forward to collaborate with key stakeholders as our buildout continues. Learn more about our unique approach: www.artbio.com #nuclearmedicine #radiopharmaceuticals https://lnkd.in/e2vCNEdN https://lnkd.in/e7fyX2pu

At the DDW Cancer Research Summit 2023, Andreas Dreps and Muaiad Kittaneh discuss important issues in antibody drug development such as choosing the right biomarker, drug formulation and manufacturing considerations. Learn more. https://ow.ly/N8pu50QhRgs

Whether you attended AACR this year or not, as the dust settles here’s your TPD related breakdown of what happened.   🔎 Beacon identified 136 (25 clinical and 111 preclinical) TPD related abstracts. 📈Bivalent degraders were by far the most frequently investigated therapeutic class. 👶 95% of abstracts investigating bivalent degraders were preclinical (only 4 clinical). 🦚 2 Preclinical abstracts for novel modality non-degrading molecular glues (IK-595 from Ikena Oncology and NEST-1 from Nested Therapeutics) P.s Here's a sneak peek of some abstract analysis by target: https://lnkd.in/eipcBECG

There’s no better time to start your data capture of in vivo oncology, in vitro, and biomarker studies with CrownLink™. Our customer portal is designed to fit your needs with benefits of capturing and monitoring study data without the hassle of a manual process. Experience the benefits of a streamlined workflow today. Register for free https://bit.ly/3tOGXRo #InVitro #InVivo #Oncology #Biomarkers #Biotech #Bioscience

BT8009, a Nectin-4 targeted BTC, developed by Bicycle Therapeutics, represents a novel class of anti-cancer agents that combine the high specificity of small peptides with potent cytotoxic payloads.  The drug has lower molecular weight and shorter plasma half-life than antibody drug conjugates, with potential to rapidly penetrate tumors and minimize healthy tissue exposure. The ongoing Phase I/II (NCT04561362) Duravelo-1 trial evaluating BT8009 as monotherapy in enfortumab vedotin-naive patients with metastatic urothelial carcinoma offers significant insights into the emerging role of Bicycle Toxin Conjugates in oncology. Updated results from BT8009 monotherapy at recommended Phase II dose of 5 mg/m2 weekly were presented at the ESMO - European Society for Medical Oncology 2024 conference. Access Unmatched Expert Insights and Comprehensive Analysis with DelveInsight Business Research LLP's ESMO 2024 Exclusive Coverage @ https://lnkd.in/gJPmrkeb #esmo #esmo2024 #esmoconference #conference #esmocoverage #detailedinsights #pharma #pharmaceutical

After spending some time reflecting on our time at ASCO 2024, Magnolia is thrilled to share our recent whitepaper on the evolving landscape of precision medicine in oncology, a key topic of discussion at the conference. This paper summarizes key trends from ASCO including biomarker reevaluation, targeted therapy augmentation, dosing optimization, and pan-tumor applications. We dive into implications for market research and pharma strategy to account for these shifting mindsets in patient management. Check it out here https://lnkd.in/gyAX_YBW or reach out to us if you would like to learn more about our ongoing work to stay on the cutting edge of the oncology space.   #PrecisionMedicine #Oncology #ASCO2024 #Marketresearch #healthsciences #MagnoliaInnovation

Antibody-drug conjugates are among the most promising drug classes in oncology. In our recent on-demand webinar, CAS experts explore the latest trends in #ADC innovation and the complications of understanding the #IP landscape in this area. https://ow.ly/fa6m50QexaP